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Purpose. To synthesize fluorescent analogues of hPept1 substrates,
FITC-Val-OCH3, Lys-FITC-OH, and Lys-FITC-OCH3, and to char-
acterize their hPept1 transporter-mediated uptake.
Methods. FITC analogues of amino acids were synthesized using es-
tablished synthetic procedures, and the extent of their [3H]Gly-Sar
uptake inhibition in HeLa/hPept1 cells was determined. The uptake
of Lys-FITC-OCH3 was evaluated in HeLa, HeLa/hPept1, and
Caco-2 cells in the presence and absence of Gly-Sar using a fluores-
cence microscopy-based assay. The uptake and transport of the Lys-
FITC analogues were also determined in Caco-2 cells using HPLC
assays.
Results. In HeLa/hPept1 cells, [3H]Gly-Sar uptake was significantly
inhibited by Lys-FITC-OCH3 (74%) but not by FITC-Val-OCH3
(22%). The uptake of Lys-FITC-OCH3 (100 M) was approximately
10-fold higher in HeLa/hPept1 cells. Also, Lys-FITC-OCH3 (100 M)
uptake in HeLa/hPept1 and Caco-2 cells was reduced by 77% and
80%, respectively, in the presence of 1 mM Gly-Sar. Dipeptides and
cephalexin significantly reduced Lys-FITC-OCH3 uptake in Caco-2
cells. The apical permeability of Lys-FITC-OCH3 (1.5 × 10
6 cm/s) in
Caco-2 cells was significantly lowered in the presence of Gly-Sar.
Fluorescence micrographs revealed that this analogue was localized
in the cytoplasm and in the nucleus.
Conclusions. The combined results indicate that Lys-FITC-OCH3 is
recognized and transported by hPept1 in HeLa/hPept1 and by pep-
tide transporters in Caco-2 cells. The results also suggest that Lys-
FITC-OCH3 might be a useful fluorescent substrate for rapid assess-
ment of peptide transporter activity in cells of interest.
KEY WORDS: fluorescent substrate; oligopeptide transporter;
hPept1; HeLa; Caco-2; permeability.
INTRODUCTION
The human intestinal di/tripeptide transporter, hPept1,
plays a nutritional role in transporting dietary peptides; how-
ever, in some cases it serves as a carrier for pharmacologically
active peptide-like compounds. Because of its broad substrate
specificity, the transporter is also known to contribute to the
intestinal absorption of several nonpeptide drug compounds
including oral -lactam antibiotics (1), the antineoplastic
agent bestatin (2), and an angiotensin-converting enzyme in-
hibitor (3). This wide substrate specificity allows the design of
peptidomimetic prodrugs to increase the intestinal transport
of low-permeability drug compounds or to potentially target
tumor cells with anticancer drugs. This approach has been
successful in increasing the bioavailability of the antiviral
drugs acyclovir and ganciclovir. Nucleoside antivirals such as
acyclovir and ganciclovir are polar drugs with low membrane
permeability and poor oral absorption (4,5). The L-valyl ester
prodrugs valacyclovir and valganciclovir increase their parent
drug bioavailability three- to fivefold (6) and 10-fold (7), re-
spectively, in humans because of their affinity for hPept1
(8,9). Targeted delivery of drugs to cancer cells would be
possible if the peptide transporter exhibits differential expres-
sion in cancer cells compared to normal healthy cells. Pan-
creatic tumors have been shown to express higher levels of
Pept1 than normal pancreatic cells (10), thereby providing a
potential target for delivery of anticancer drugs. Based on this
rationale, the in vitro delivery of -aminolevulinic acid to rat
pancreatic tumor cells via the Pept1 transporter has been re-
ported (11).
The peptide transporters are capable of carrying natural
substrates up to at least 522 Daltons (tritryptophan) (12). The
promiscuous nature of the hPept1 transporter, together with
its ability to carry “large” substrates, makes it an attractive
carrier for anticancer compounds. The characterization of the
peptide transporter uptake activity in different cell types in
vitro or different tissues in vivo could require the screening of
many samples. In particular, if cancer cell libraries need to be
screened rapidly, suitable alternatives to tedious HPLC or
hazardous radioactive assays would be highly beneficial.
Fluorescence-based assays offer high sensitivity and are ame-
nable to rapid assessment with multiwell plate readers. Sev-
eral studies with fluorescent peptide transporter substrates
have been reported. In one such study, fluorescent peptide
analogues of Val-Lys and Lys-Sar were synthesized by Abe et
al. and examined for their transport in Caco-2 cells (13). The
authors found that although the fluorescent analogues do not
appear to be transported in Caco-2 cells, they did exhibit high
affinity for the transporter (13). Groneberg et al. reported the
synthesis and ex vivo uptake studies of D-Ala-Lys-AMCA
(7-amino-4-methylcoumarin-3-acetic acid) in murine small in-
testine (12). The authors demonstrated and visualized mam-
malian intestinal peptide transport ex vivo and identified the
cellular sites of Pept1 expression in the intestinal tract and
suggest that such visualization assays might be a useful tool to
characterize compounds that use Pept1 for uptake into epi-
thelial cells or that inhibit transport activity specifically.
In this study we report the synthesis of fluorescent ana-
logues of the amino acids valine and lysine, FITC-Val-OCH3,
Lys-(N-FITC)-OH (Lys-FITC-OH), and Lys-(N-FITC)-
OCH3 (Lys-FITC-OCH3), by conjugation of the -amino
group of Val or the -amino group of Lys or its methyl ester
to the fluorescent molecule fluorescein isothiocyanate
(FITC). The fluorescent analogues were then tested for their
ability to inhibit the uptake of [3H]Gly-Sar, a Pept1 substrate,
in HeLa cells overexpressing hPept1. We further describe the
cellular uptake of Lys-FITC-OCH3 in normal HeLa cells, in
HeLa cells overexpressing hPept1, and in Caco-2 cells in the
presence and absence of Gly-Sar using a simplified fluores-
cence assay. The uptake profiles obtained using fluorescence-
based assays were corroborated using conventional HPLC
and radioactivity methods. The involvement of hPept1 in me-
diating active transport of Lys-FITC-OCH3 and its free acid
form was also examined with transport studies in Caco-2
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monolayers and with conventional fluoroscopic images of
Lys-FITC-OCH3 uptake in HeLa/hPept1 cells.
MATERIALS AND METHODS
Materials
[3H]-Glycyl-sarcosine (sp. act., 400 mCi/mmol) was pur-
chased from Moravek Biochemicals (Brea, CA). All other
chemicals were purchased from Sigma (St. Louis, MO) unless
otherwise specified. Cell culture reagents were obtained from
Gibco (Grand Island, NY), and cell culture supplies were
from Corning (Corning, NY) and Falcon (Lincoln Park, NJ).
Cell Culture
Caco-2 cells were obtained from American Type Culture
Collection (ATCC HTB37, Passage number 30-35) and were
maintained in Dulbecco’s modified Eagle’s medium
(DMEM) supplemented with 10% fetal bovine serum (FBS),
1% MEM nonessential amino acids, 1 mM sodium pyruvate,
and 1% L-glutamine. HeLa cells were obtained from ATCC
and grown in similar conditions. All cells were grown in an
atmosphere of 5% CO2 and 90% relative humidity at 37°C.
RT-PCR Assay for hPept1 mRNA Expression
For RT-PCR, total RNA from the tissue and cell samples
was purified using Trizol reagent (Gibco, Grand Island, NY).
One microgram of total RNA from each sample was sub-
jected to RT-PCR (PCR Access system, Promega, Madison,
WI) using hPept1 specific primers. The primers corresponded
to nucleotide positions 342–360 (forward primer) and 1575–
1592 (reverse primer) of the cDNA. The first strand cDNA
was synthesized using AMV reverse transcriptase (AMV RT)
at 48°C for 45 min. This was followed by a 2-min cycle at 94°C
to inactivate AMV RT and to denature the primers and
cDNA. The PCR was performed for 25 cycles of 94°C for
30 s, primer annealing for 1 min at 54°C, extension at 68°C for
2 min, and a final extension at 68°C for 7 min. The experi-
mental conditions were optimized to ensure linear amplifica-
tion of the PCR product. The expected hPept1 PCR fragment
was 1.2 kb. The reaction mixture was separated on a 4–20%
TBE -polyacrylamide gel (Invitrogen, Carlsbad, CA) and vi-
sualized with SYBR Green nucleic acid gel stain (Molecular
Probes, Eugene, OR).
Adenoviral Infection of HeLa Cells
Ad.RSVhPept1 was prepared and was used to infect
HeLa cell cultures as described by Hsu et al. (14). The HeLa
cells were seeded onto six-well plates at a density of 1 × 105
cells/cm2 and grown for 24 h. The cells were infected with
5000 viral particles per cell, and uptake experiments were
conducted at 48 h postinfection.
Lys-(N-FITC)-OH and Lys-(N-FITC)-OCH3 Synthesis
Boc-Lys-OH or Boc-Lys-OCH3 (0.67 mmol) was dis-
solved in 20 ml dimethylformamide (DMF) and cooled to
0°C. To this 237 mg (0.61 mmol) fluorescein-5-isothiocyanate
(FITC) and 93 l (0.67 mmol) of triethylamine (Et3N) were
added. After stirring at 0°C for 15 min and then at room
temperature for 2 h, the reaction mixture was diluted with 50
ml ethyl acetate and washed successively with 0.6 M citric acid
(40 mL), water (30 mL), and brine (20 mL). The organic layer
was dried over sodium sulfate and concentrated under
vacuum. The resulting residue was purified by column chro-
matography using a mixture of chloroform:methanol:acetic
acid (15:1:0.08, v/v) as solvent. After evaporation of the de-
sired fractions, the obtained yellow intermediate was treated
with 10 ml of trifluoroacetic acid /CH2Cl2 (1:1, v/v) and stirred
at 0°C for 30 min. The excess acid was removed in vacuo. The
resulting residue was triturated with diethylether (Et2O) and
dried in vacuo to obtain the desired product as an orange
powder. The overall yield for the two lysine-FITC analogues
was ∼91%. Electrospray ionization mass spectra (ESI-MS)
were obtained on a Thermoquest LCQ electrospray ioniza-
tion mass spectrometer. The observed molecular weights of
the FITC analogues were found to be similar to those pre-
dicted from their expected structures. Lys-FITC-OH, ESI-MS
m/z  536.0 (M+H)+; Lys-FITC-OCH3, ESI-MS m/z  549.9
(M+H)+. The FITC analogue structures are shown in Fig. 1.
Val-FITC-OCH3 Synthesis
Val-OCH3 (0.67 mmol) was dissolved in 20 ml DMF and
cooled to 0°C. To this 237 mg (0.61 mmol) of FITC and 93 l
(0.67 mmol) of Et3N were added. After stirring at 0°C for 15
min and then at room temperature for 2 h, the reaction mix-
Fig. 1. Structures of Lys-(N-FITC)-OH, Lys-(N-FITC)-OCH3, and
FITC-Val-OCH3.
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ture was diluted with 50 ml ethyl acetate and washed succes-
sively with 0.6 M citric acid (40 ml), water (30 ml), and brine
(20 ml). The organic layer was dried over sodium sulfate and
concentrated under vacuum. The resulting residue was puri-
fied by column chromatography using a mixture of chloro-
form:methanol:acetic acid (15:1:0.08, v/v) as solvent. After
evaporation of the desired fractions, the residue was tritu-
rated with Et2O and dried in vacuo to obtain the desired
product as an orange powder. The overall yield was 90%.
Electrospray ionization mass spectra (ESI-MS) were obtained
on a Thermoquest LCQ electrospray ionization mass spec-
trometer. The observed molecular weight of the FITC ana-
logue was found to be similar to those predicted from its
expected structure. Val-FITC-OCH3, ESI-MS m/z  521.1
(M+H)+. The Val-FITC-OCH3 structure is shown in Fig. 1.
HPLC Assay of FITC Analogues
Samples containing the Lys-FITC analogues were ana-
lyzed using a high-performance liquid chromatography
(HPLC) system consisting of a pump (Waters, Model 510,
Milford, MA), an automatic injector (Waters, WISP model
712), a reversed-phase column (Ultrasphere, 5-m, C-18,
4.6 × 250 mm, Beckman), and a fluorescent detector (Waters,
Model 470) set at an excitation wavelength of 490 nm and an
emission wavelength of 525 nm. The mobile phase was a (82/
18, v/v) mixture of phosphate-buffered saline (pH 7.0) and
acetonitrile. The compounds were analyzed over 23 min at a
flow rate of 1 ml/min. The pump, data acquisition, and inte-
gration were controlled with Millennium® software (Waters).
Fluorescent Uptake Assays
The culture medium in the six-well culture plate was re-
moved, the cells were washed with PBS pH 7.4, and 2 ml of
uptake medium containing (25–100 M) Lys-FITC-OCH3
was added to the wells. The uptake medium contained 145
mM NaCl, 3 mM KCl, 1 mM NaH2PO4, 1 mM CaCl2, 0.5 mM
MgCl2, 5 mM D-glucose, and 5 mM MES (pH 6.0). The fluo-
rescent analogue was incubated with the cells for 45 min at
37°C, after which the buffer was removed, and the cells were
washed three times with room-temperature PBS. Lys-FITC-
OCH3 uptake was determined by fluorescence measurements
using an inverted fluorescence microscope (Zeiss Axiovert
135 TV). For each treatment, multiple images were randomly
taken using the 10× objective from independent wells and
then quantified using image analysis (Metamorph, Universal
Imaging Corp., Downingtown, PA). The cells were then
scraped off in water, lysed by probe-sonication for 15 s three
times, and protein concentration was determined with a Pro-
tein Assay DC kit (BioRad, Hercules, CA). After subtraction
of background fluorescence, the fluorescent intensity of each
image was integrated and reported as an integrated fluores-
cence value per milligram of protein (integrated value/mg
protein).
Fluorescence Micrographs of Lys-FITC-OCH3 Uptake in
HeLa/hPept1 Cells
HeLa cells were grown on chamber slides (Nalge
Nunc International, Rochester, NY) and infected with
Ad.RSVhPept1 as previously described (14). Lys-FITC-
OCH3 (50 M) was incubated with the cells for 45 min at
37°C in uptake buffer, after which the buffer was removed,
and the cells were washed three times with cold uptake buffer.
The HeLa/hPept1 cells were fixed with 4% paraformaldehyde
for 15 min at 4°C and washed 4 times with PBS at room
temperature. The slides were mounted in Fluoromount-G
medium (Electron Microscopy Sciences, Fort Washington,
PA), and micrographs of cell images were obtained using an
inverted fluorescence microscope (Zeiss Axiovert 135 TV)
with 50× and 100× objectives.
Caco-2 Monolayer Transport and Stability Studies
The Caco-2 permeability of Lys-FITC-OH, Lys-FITC-
OCH3, and FITC-Val-OCH3 (50 M) were evaluated as pre-
viously described (15). The transport of the FITC analogues
in the apical-to-basolateral (AP-to-BL) and in the basolat-
eral-to-apical (BL-to-AP) directions was determined with and
without Gly-Sar (10 mM) in collagen-coated transwell pates
(0.4 m pore size, 12 mm diameter, Costar, Cambridge, MA).
The concentration of the FITC analogue in the receiver and
donor compartments were analyzed using HPLC. The appar-
ent permeability (Papp) in either direction was calculated us-







where Vr is the receiver volume, A is the surface area of the
exposed monolayer, C0 is the concentration of the FITC ana-
logue in the donor solution, and dCr/dt is the rate of change of
concentration in the receiver solution.
The stability of donor solutions of Lys-FITC-OCH3 and
Lys-FITC-OH bathing either the apical side or the basolateral
side was examined at 90 min of the transport experiments.
The samples were assayed with HPLC to determine the mode
and extent of degradation of the analogues when in contact
with Caco-2 monolayers. The receiver solution in AP-to-BL
transport experiments was also assayed with HPLC to deter-
mine metabolism of the analogues following passage across
Caco-2 cells.
Inhibition Studies
For [3H]Gly-Sar uptake inhibition assays, cells were
seeded in 12-well culture plates (3.8 cm2 growth area) at a
density of 105 cells/cm2. Two days postinfection, HeLa/hPept1
cells were washed with pH 6.0 uptake buffer before addition
of substrates and inhibitors. Solutions containing 1 mM of the
test FITC analogue and 20 M [3H]Gly-Sar (0.4 Ci/ml) was
added to each well and incubated for 30 min at 25°C. The cells
were then washed with ice-cold pH 6.0 uptake buffer three
times to stop cellular uptake. One milliliter of 1 M NaOH/
1.5% Triton X-100 was then added to each well and incubated
for 30 min at 25°C. The cells were scraped off and transferred
into vials containing 4 ml of scintillation cocktail. The samples
were analyzed for [3H]Gly-Sar content by scintillation count-
ing (Beckman LS-9000, Beckman Instruments, Fullerton,
CA), and the protein concentrations determined.
In a second inhibition assay, Lys-FITC-OCH3 uptake
into Caco-2 cells was determined in the presence of the di-
peptides Gly-Pro and Gly-Phe and in the presence of Lys or
cephalexin. Thus, Lys-FITC-OCH3 uptake from solutions
containing 50 M Lys-FITC-OCH3, and known concentra-
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tions of the inhibitors were determined and compared to that
from a control solution. The inhibitor concentrations used
were as follows: 30 mM lysine, 10 mM Gly-Pro, 10 mM Gly-
Phe, and 10 mM cephalexin. One milliliter of the test solution
was added to cells and agitated on a plate shaker at 25°C.
After 30 min incubation, the cells were washed with cold
uptake buffer three times, water was added, and cells were
scraped and probe-sonicated three times for 15 s. The lysate
was treated with TCA (3–5%), vortexed, and centrifuged 5
min at 3000 rpm. The supernatant was filtered through a 0.45-
m membrane filter and analyzed by HPLC. The protein
concentration was determined from the pre-TCA-treated
sample using the Protein Assay DC kit (BioRad).
RESULTS
RT-PCR Assay for hPept1 mRNA Expression
The hPept1 mRNA expression results from HeLa, HeLa/
hPept1, and Caco-2 cells are shown in Fig. 2. A 1.2-kb product
was detected in all three samples, confirming the presence of
hPept1 in all three cells. A semiquantitative estimate of
mRNA expression using RT-PCR suggests that expression
was in the order HeLa/hPept1 > Caco-2 cells > HeLa cells.
The hPept1 mRNA expression was quite insignificant in nor-
mal HeLa cells, whereas its expression in HeLa/hPept1 cells
was about 6-fold and 2-fold higher compared to normal HeLa
cells and Caco-2 cells, respectively.
[3H]Gly-Sar Uptake Inhibition by FITC Analogues in
HeLa/hPept1 Cells
The [3H]Gly-Sar uptake results in the presence and ab-
sence of Lys-FITC-OCH3 or FITC-Val-OCH3 in HeLa/
hPept1 cells are shown in Fig. 3. It is evident that both the
FITC analogues were capable of inhibiting Gly-Sar uptake,
suggesting their affinity for the hPept1 transporter. However,
Gly-Sar uptake inhibition was quite significant with Lys-
FITC-OCH3 (74%, p < 0.001), compared to only 22% with
FITC-Val-OCH3. Thus, Lys-FITC-OCH3 appears to exhibit a
much higher affinity for hPept1 than FITC-Val-OCH3 and
was chosen for more detailed uptake and inhibition studies.
Fluorescence Assays of Lys-FITC-OCH3 Uptake in HeLa
and HeLa/hPept1 Cells
The uptake results of 100 M Lys-FITC-OCH3 in normal
HeLa and HeLa/hPept1 cells determined using a fluorescence
assay are shown in Fig. 4. The results in Fig. 4 clearly indicate
that Lys-FITC-OCH3 uptake is approximately 10-fold higher
in HeLa cells overexpressing hPept1. The uptake of 100 M
Lys-FITC-OCH3 in HeLa/hPept1 cells was found to be sig-
Fig. 2. RT-PCR quantification of hPept1 mRNA in Caco-2 and HeLa
cells. Lane 1, MW markers; lane 2, Caco-2 cell RNA; lane 3, HeLa
cell RNA; lane 4, HeLa cell RNA from cells infected with adenovi-
rus-containing hPept1.
Fig. 3. Lys-FITC-OCH3 (1 mM) and FITC-Val-OCH3 (1 mM) inhi-
bition of [3H]Gly-Sar uptake (20 M, 0.5 Ci/ml) in HeLa/hPept1
cells (mean ± SD, n  4).
Fig. 4. The uptake of Lys-FITC-OCH3 (100 M) in HeLa/hPept1
and normal HeLa cells. Gly-Sar (1 mM) was used as an inhibitor in
the virus-infected HeLa/hPept1 cells. HeLa/hPept1 cells treated with
100 M Lys-FITC-OCH3 (mean ± SEM, nine wells); HeLa/hPept1
treated with 1 mM Gly-Sar and 100 M Lys-FITC-OCH3 (mean ±
SEM, six wells); HeLa cells treated with 100 M Lys-FITC-OCH3
(mean ± SEM, nine wells).
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nificantly inhibited (77%; p < 0.001) in the presence of 1 mM
Gly-Sar, indicating competitive hPept1 transport (Fig. 4).
The Lys-FITC-OCH3 uptake in HeLa and HeLa/hPept1
cells at three different concentrations (25, 50, and 100 M)
determined with fluorescence assays is shown in Table I. The
Lys-FITC-OCH3 uptake in HeLa/hPept1 cells increased with
Lys-FITC-OCH3 concentration and appears to show satu-
rable behavior beyond 50 M. Thus, the enhancement in up-
take from 25 M to 50 M was about 5.5-fold, whereas it
increased only about 1.5-fold with increasing concentration
from 50 M to 100 M. It was also found that Lys-FITC-
OCH3 uptake in HeLa/hPept1 cells was 10- to 100-fold higher
than the uptake in normal HeLa cells at a given concentra-
tion. On the other hand, uptake of Lys-FITC-OCH3 in nor-
mal HeLa cells exhibited a relatively large increase at the
highest concentration of 100 M examined compared to that
at 25 M and 50 M.
Fluorescence Assays of Lys-FITC-OCH3 Uptake in
Caco-2 Cells
The uptake of 100 M Lys-FITC-OCH3 in Caco-2 cells
determined with fluorescence assays in the presence and ab-
sence of 1 mM Gly-Sar is shown in Fig. 5. The extent of
Lys-FITC-OCH3 uptake inhibition by 1 mM Gly-Sar (80%),
was similar to the Lys-FITC-OCH3 uptake inhibition seen in
HeLa/hPept1 cells (Fig. 4). More interestingly, the fluores-
cent uptake intensities of 100 M Lys-FITC-OCH3 in HeLa,
Caco-2, and HeLa/hPept1 cells determined under similar ex-
perimental conditions (integrated value/mg protein values of
250,000, 500,000 and 2,450,000) appear to be related to
hPept1 mRNA expression levels (Fig. 2). Although the
hPept1 mRNA expression levels are not quite quantitative,
the enhanced fluorescent intensities with increased hPept1
expression in the three cells further supports cellular uptake
of the FITC analogue via hPept1-mediated transport.
HPLC Assays of Lys-FITC-OCH3 Uptake Inhibition in
Caco-2 Cells
The Caco-2 uptake results of 50 M Lys-FITC-OCH3 in
the presence of several inhibitors that were quantified using
HPLC assays are shown in Fig. 6. Thus, the small dipeptides
Gly-Pro and Gly-Phe, as well as cephalexin, known hPept1
substrates, significantly reduced Lys-FITC-OCH3 uptake (p <
0.01). The extent of inhibition was 44% by Gly-Pro, 68% by
Gly-Phe, and 67% by cephalexin. Uptake inhibition by lysine
was found to be insignificant (5%). These results obtained
through assay of cellular Lys-FITC-OCH3 content using
HPLC corroborate that cellular uptake of the FITC analogue
occurs via a peptide transporter-mediated pathway.
Fluorescence Micrographs of Lys-FITC-OCH3 Uptake in
HeLa/hPept1 Cells
Typical fluorescence micrographs of HeLa/hPept1 cells
incubated with Lys-FITC-OCH3 using cell microscopy under
high magnification (50×) with an inverted fluorescence mi-
croscope are shown in Fig. 7. The micrographs indicate that
the chromophore is localized in the cytoplasm as well as in the
nucleus. In contrast, no fluorescence was evident with normal
HeLa cells, indicating negligible uptake into cells or cell sur-
face binding.
Caco-2 Permeability and Lys-FITC Analogue Stability
The apparent permeabilities of the three FITC analogues
in the apical-to-basolateral (AP-to-BL) direction are shown
in Table II. The AP-to-BL permeability of Lys-FITC-OCH3
Fig. 6. Inhibition of Lys-FITC-OCH3 uptake in Caco-2 cells. Control
0.05 mM, Lysine 30 mM, Gly-Pro 10 mM, Gly-Phe 10 mM, cephalexin
10 mM (mean ± SEM, four wells).
Table I. Lys-FITC-OCH3 Uptake in Normal HeLa and HeLa/hPept1






25 0.03 ± 0.01 3.03 ± 1.83b
50 0.16 ± 0.13 16.58 ± 3.43b
100 2.51 ± 0.88 24.24 ± 3.14b
a All values expressed as mean ± SEM of experiments from 9–10
wells.
b p-value < 0.001 compared to corresponding uptake in normal HeLa
cells.
Fig. 5. Caco-2 cell uptake of 100 M Lys-FITC-OCH3 with and with-
out 1 mM Gly-Sar inhibitor (mean ± SEM, nine wells each); p < 0.001.
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was similar to that observed for Lys-FITC-OH, indicating that
both analogues are equally permeable. In comparison, the
AP-to-BL permeability of Val-FITC-OCH3 was about 10-fold
lower than that of the Lys-FITC analogues. Further, the pres-
ence of 10 mM Gly-Sar significantly inhibited the permeabil-
ity of both Lys-FITC analogues (p < 0.001). The basolateral-
to-apical (BL-to-AP) permeabilities of the two Lys-FITC
analogues were similar to each other and roughly 7-fold lower
than their AP-to-BL permeability (Table II). Interestingly,
the AP-to-BL permeability of Lys-FITC-OCH3 in the pres-
ence of 10-mM Gly-Sar was similar to its BL-to-AP perme-
ability. The effect of 10 mM Gly-Sar on AP-to-BL permeabil-
ity as well as BL-to-AP permeability of Val-FITC-OCH3 was
not determined.
The stability results on the donor Lys-FITC analogue
solutions bathing either the apical or basolateral side are
shown in Table III. It is seen that the free acid analogue is
stable over 90 min with almost no degradation or breakdown
of the thiourea linkage when in contact with either side of the
Caco-2 monolayers. The methyl ester analogue, however, de-
graded to the free acid form on the apical side (∼53% in 90
min). The degradation of Lys-FITC-OCH3 was lower when
placed on the basolateral side. Further, only the free acid
form, Lys-FITC-OH, was detected in the receiver solution in
AP-to-BL experiments.
DISCUSSION
There are a wide range of substrates that exhibit affinity
for the hPept1 oligopeptide transporter. This substrate flex-
ibility allows the design of prodrugs that are targeted to
hPept1 using substrates with an equally wide range of sub-
strate moieties. Thus, it is anticipated that following prodrug
design and synthesis, the characterization of hPept1 trans-
porter uptake activity in different cell types in vitro or differ-
ent tissues in vivo would require the screening of numerous
samples. In these situations, suitable alternatives to tedious
HPLC or hazardous radioactive assays would be highly ben-
eficial. Fluorescence-based assays not only obviate the use of
hazardous materials but also are amenable to rapid screening
with multiwell plate readers. The present study demonstrates
this applicability with fluorescently labeled analogues using
cells with widely differing levels of hPept1 expression. Thus,
HeLa cells, HeLa cells overexpressing hPept1, and normal
Caco-2 cells were analyzed for hPept1 mRNA expression lev-
els. The semiquantitative RT-PCR results in Fig. 2 indicate
that uptake of hPept1 substrates should be consistent with the
order of hPept1 mRNA expression, HeLa < Caco-2 < HeLa/
hPept1.
In initial studies, fluorescent analogues of the amino ac-
ids valine and lysine were synthesized and tested in HeLa/
hPept1 cells. The fluorescent moiety fluorescein isothiocya-
nate (FITC) was linked to the methyl ester of valine via the
N-terminal amino group of valine or to the N amino group of
lysine or its methyl ester. The rationale for this synthesis was
based on the previously successful amino acid prodrug strat-
egy used with valacyclovir. Modifications were made with the
knowledge that the basic structural requirement for peptide
transport is the terminal carboxyl group of the amino acid and
that the N-terminal of the amino acid could be altered with-
out affecting affinity for the hPept1 transporter (16). The
[3H]Gly-Sar inhibition results shown in Fig. 3 clearly suggest
that both methyl ester FITC analogues have affinity for
hPept1. However, the lower affinity of FITC-Val-OCH3
(22% inhibition), a neutral molecule, may be caused by its
enhanced lipophilicity. The 10-fold lower AP-to-BL perme-
ability of FITC-Val-OCH3 in Caco-2 cells compared to that of
Lys-FITC-OCH3 is consistent with its lower peptide trans-
porter affinity. The charged lysine analogue Lys-FITC-OCH3,
however, exhibited a much higher hPept1 affinity judging
from its ability to inhibit 74% of [3H]Gly-Sar uptake in HeLa/
hPept1 cells. The similar AP-to-BL permeabilities of Lys-
FITC-OH and Lys-FITC-OCH3 may suggest that the struc-
tural requirements of a peptide bond and a free carboxyl
group may not be necessary for hPept1 recognition and trans-
Table II. Transport of FITC Analogues in Caco-2 Cell Monolayersa
Compound
Permeabilityb (×106 cm/s)
AP to BL BL to AP
Lys-FITC-OCH3 1.47 ± 0.10 0.20 ± 0.03
Lys-FITC-OCH3 + GlySar 0.26 ± 0.03
c nd
Val-FITC-OCH3 0.12 ± 0.02 nd
Lys-FITC-OH 1.51 ± 0.17 0.21 ± 0.03
Lys-FITC-OH + GlySar 0.71 ± 0.08c nd
a All values expressed as mean ± SD of triplicate determinations at
37°C.
b FITC-Lys analogue concentration, 50 M; Gly-Sar concentration,
10 mM.
c p  0.002 compared to control.
Fig. 7. Lys-FITC-OCH3 uptake into HeLa/hPept1 cells.
Table III. Stability of FITC Analogues in Caco-2 Cell Monolayersa
Compound
Stabilityb
AP donor BL donor
Lys-FITC-OCH3 47.6 ± 5.3 70.4 ± 1.5
Val-FITC-OCH3 nd nd
Lys-FITC-OH ∼100.0 ∼100.0
a All values expressed as mean ± SD of triplicate determinations at
37°C.
b Percentage compound remaining in donor bathing solution at 90
min.
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port. It is important to note, however, that the permeability of
Lys-FITC-OCH3 was affected to a greater extent in the pres-
ence of Gly-Sar, indicating some preference for the methyl
ester form by the peptide transporter (Table II).
The high stability of Lys-FITC-OH in Caco-2 monolayer
bathing solutions clearly suggests that the thiourea linkage
between FITC and lysine remains intact. Thus, the loss of
Lys-FITC-OCH3 from bathing solutions resulted from con-
version of the methyl ester to its free acid form. This obser-
vation coupled with the finding that AP-to-BL permeability
of the two forms in Caco-2 monolayers is similar indicates
that such degradation may not be a major factor in uptake
determinations. The inability to detect the methyl ester ana-
logue in receiver solutions in AP-to-BL experiments suggests
its rapid hydrolysis by brush border membrane enzymes and
cytosolic enzymes during transit.
The fluorescence uptake intensities of 100 M Lys-
FITC-OCH3 in HeLa, HeLa/hPept1 cells (Fig. 4), and in
Caco-2 cells (Fig. 5) determined under similar experimental
conditions is consistent with the order of hPept1 mRNA ex-
pression levels in the three systems (Fig. 2). Further, the sig-
nificant reduction of Lys-FITC-OCH3 fluorescence intensities
in the presence of Gly-Sar in both HeLa/hPept1 (Fig. 4) and
Caco-2 (Fig. 5) cells provides strong evidence for hPept1-
mediated uptake. The saturable uptake behavior of Lys-
FITC-OCH3 with HeLa/hPept1 cells at higher Lys-FITC-
OCH3 concentrations also suggests hPept1 carrier-mediated
transport of the analogue. It is possible that Lys-FITC-OCH3
might also be a substrate for hPept2 transporter or other
peptide transporters. However, the predominance of hPept1
expression in hPept1 overexpressed HeLa cells and the ab-
sence of hPept2 in Caco-2 cells indicate that in the two cell
systems examined, the contribution of hPept2 to uptake and
transport of Lys-FITC-OCH3 is quite negligible. Thus, the
results suggest that the fluorescent analogue Lys-FITC-OCH3
exhibits high affinity for hPept1 and that Lys-FITC-OCH3
uptake in test candidate cells or tissues via the hPept1 trans-
porter can be conveniently monitored with simple fluores-
cence measurements.
The Lys-FITC-OCH3 uptake into Caco-2 cells deter-
mined using HPLC assays shown in Fig. 6 and uptake into
HeLa/hPept1 cells using cell microscopy shown in Fig. 7 pro-
vide complementary evidence for uptake of the fluorescent
analogue. Further, the inhibitory effects of known hPept1
substrates such as Gly-Sar, Gly-Pro, Gly-Phe, and cephalexin
on Lys-FITC-OCH3 uptake and transport across Caco-2 cells
determined by HPLC analysis as well as the negligible effect
of Lys on uptake (Fig. 6 and Table II), clearly suggest that
Lys-FITC-OCH3 is transported via the hPept1 transporter.
The HPLC results also suggest that monitoring of Lys-FITC-
OCH3 uptake in cells with fluorescence measurements would
be a reliable alternative.
CONCLUSIONS
In this study, we have demonstrated that the fluorescent
analogue Lys-FITC-OCH3 is a substrate for the hPept1 trans-
porter. Thus, fluorescent intensities of Lys-FITC-OCH3 up-
take in HeLa, Caco-2, and HeLa/hPept1 cells corresponded
to the extent of hPept1 mRNA expression in the cells. The
effect of known hPept1 substrates on Lys-FITC-OCH3 up-
take in HeLa/hPept1 cells determined using fluorescence
measurements was also consistent with hPept1-mediated up-
take of the fluorescent analogue. The Lys-FITC-OCH3 up-
take in Caco-2 cells and its inhibition by known hPept1 sub-
strates determined with HPLC analyses provided evidence
for the reliability of the fluorescence method. The inhibition
of Lys-FITC-OCH3 transport in the presence of Gly-Sar in
Caco-2 cells and the direct evidence of chromophore local-
ization in the cytoplasm and nucleus corroborate the fluores-
cence uptake studies. Finally, although the fluorescence up-
take methodology described in this study is not set up as a
high-throughput strategy, it can be easily adapted for such an
approach. It is anticipated that with such a high-throughput
method, large numbers of cell samples can be screened rap-
idly and accurately for hPept1 uptake activity.
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